Metabolic syndrome (Mets) is a clinical condition characterized by a cluster of major risk
factors for cardiovascular disease (CVD) and type 2 diabetes: proatherogenic dyslipidemia …

Hormone therapy (HT) has been used in postmenopausal women for decades in clinical
practice. With further analysis and newer studies, the benefits and risks of HT have been …

Cardiovascular diseases (CVD) are predominantly an aging disease. Important sex-specific
differences exist and the mechanism (s) by which this sex-by-age interaction influences CVD …

Estrogen plays a prominent role in regulating and coordinating energy homeostasis
throughout the growth, development, reproduction, and aging of women. Estrogen receptors …

Objective This update will address 3 areas specifically that are essential to improving
cardiovascular outcomes for women. Methods The current literature has been reviewed and …

(1) Background: Menopause is an important event in women's lives, possibly contributing to
the development of CVD, which is associated with changes in the cardiovascular risk profile …

Recent evidence shows the cardiometabolic effects of estrogen administration in
postmenopausal women. Women have a cardiometabolic advantage during their …

Menopause represents a critical life stage in women, characterized by hormonal changes
that significantly impact cardiovascular health. While the decline in estrogen levels has long …

Human life span expectancy has increased, and aging affects the organism in several ways,
leading, for example, to an increased risk of cardiovascular diseases. Age-adjusted …

Cardiovascular disease (CVD) remains a major health threat in women. While traditional
CVD risk factors such as hypertension, hyperlipidemia, diabetes, and smoking have been …